Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Qiagen N.V.    QGEN   NL0012169213

QIAGEN N.V.

(QGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • In a short-term perspective, the company has interesting fundamentals.
Strengths
  • The group's high margin levels account for strong profits.
  • The group usually releases upbeat results with huge surprise rates.
  • Over the last seven days, analysts have been revising upwards their EPS estimates for the company.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Weaknesses
  • Stock prices approach a strong long-term resistance in weekly data at USD 42.8.
  • The stock is currently in contact with a medium-term resistance that must be gotten rid of so as to resume the upward trend.
  • Based on current prices, the company has particularly high valuation levels.
  • With an expected P/E ratio at 38.5 and 31.93 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Ratings chart
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalisation (M$)Investor Rating
QIAGEN N.V.18.96%9 153
LONZA GROUP13.73%31 009
CELLTRION, INC.2.35%25 160
IQVIA HOLDINGS INC.-22.54%20 797
SEATTLE GENETICS, INC.6.66%19 875
INCYTE CORPORATION-2.53%15 874
GALAPAGOS NV-3.49%12 893
ALNYLAM PHARMACEUTICALS, IN..-4.91%12 308
MODERNA, INC.63.70%11 041
ICON PUBLIC LIMITED COMPANY-16.39%7 293
BIO-TECHNE CORPORATION-11.80%7 272
HANGZHOU TIGERMED CONSULTIN..0.06%6 779
IONIS PHARMACEUTICALS, INC.-17.12%6 582
ACADIA PHARMACEUTICALS INC.-2.50%6 563
PHARMARON BEIJING CO., LTD.0.05%6 405
CHARLES RIVER LABORATORIES ..-12.72%6 245
More Results
Financials (USD)
Sales 2020 1 560 M
EBIT 2020 432 M
Net income 2020 226 M
Debt 2020 925 M
Yield 2020 -
P/E ratio 2020 38,5x
P/E ratio 2021 31,9x
EV / Sales2020 6,46x
EV / Sales2021 5,92x
Capitalization 9 153 M
Upcoming event on QIAGEN N.V.
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes